durvalumab plus tremelimumab (n=133) vs. durvalumab alone (n=67)
randomized controlled trial
durvalumab plus tremelimumab
durvalumab (20 mg/kg every 4 weeks) plus tremelimumab (1 mg/kg every 4 weeks) for 4 cycles, followed by durvalumab (10 mg/kg every 2 weeks)
durvalumab monotherapy
durvalumab (10 mg/kg every 2 weeks) monotherapy
mHNSCC - L2 - PDL1 negative
PD-L1–low/negative disease
open-label
127 sites in north america, europe, and asia pacific
P2 / no formal statistical plan to evaluate comparison between groups. No formal statistical comparison were planned
Treatment with durvalumab monotherapy and durvalumab tremelimumab resulted in clinical benefit in patients with PD-L1–low/negative tumor cell expression, but no significant difference in efficacy
CONDOR (DT vs T ; PDL1 TC<25%), 2019 NCT02319044
durvalumab plus tremelimumab (n=133) vs. tremelimumab (n=67)
randomized controlled trial
durvalumab plus tremelimumab
durvalumab (20 mg/kg every 4 weeks) tremelimumab (1 mg/kg every 4 weeks) for 4 cycles, followed by durvalumab (10 mg/kg every 2 weeks)
tremelimumab monotherapy
tremelimumab (10 mg/kg every 4 weeks for 7 doses then every 12 weeks for 2 doses) monotherapy.
mHNSCC - L2 - PDL1 negative
PD-L1–low/negative disease
open-label
127 sites in north america, europe, and asia pacific
P2: no statistic plan to evaluate comparison between groups. No formal statistical comparison were planned
Treatment with durvalumab monotherapy and durvalumab tremelimumab resulted in clinical benefit in patients with PD-L1–low/negative tumor cell expression, but no significant difference in efficacy